Swiss National Bank’s Clovis Oncology, Inc. CLVS Stock Holding History

Swiss National Bank’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-291,900	Closed	-$590K	–	2820
2022 Q1	$590K	Buy	291,900 +44,400	+18%	+$87.2K	﹤0.01%	2563
2021 Q4	$671K	Buy	247,500 +28,600	+13%	+$106K	﹤0.01%	2598
2021 Q3	$976K	Hold	218,900	–	–	﹤0.01%	2447
2021 Q2	$1.27M	Buy	218,900 +27,200	+14%	+$159K	﹤0.01%	2361
2021 Q1	$1.35M	Buy	191,700 +5,100	+3%	+$34.2K	﹤0.01%	2223
2020 Q4	$896K	Hold	186,600	–	–	﹤0.01%	2344
2020 Q3	$1.09M	Hold	186,600	–	–	﹤0.01%	2049
2020 Q2	$1.26M	Buy	+186,600	New	+$1.41M	﹤0.01%	1961
2019 Q4	–	Sell	-83,550	Closed	-$328K	–	2554
2019 Q3	$328K	Hold	83,550	–	–	﹤0.01%	2447
2019 Q2	$1.24M	Sell	83,550 -7,700	-8%	-$139K	﹤0.01%	1993
2019 Q1	$2.27M	Buy	91,250 +2,800	+3%	+$70.2K	﹤0.01%	1590
2018 Q4	$1.59M	Buy	88,450 +1,400	+2%	+$28.6K	﹤0.01%	1718
2018 Q3	$2.56M	Buy	87,050 +3,400	+4%	+$132K	﹤0.01%	1557
2018 Q2	$3.8M	Buy	83,650 +2,800	+3%	+$136K	﹤0.01%	1274
2018 Q1	$4.27M	Buy	80,850 +1,800	+2%	+$105K	0.01%	1142
2017 Q4	$5.38M	Buy	79,050 +2,600	+3%	+$182K	0.01%	1006
2017 Q3	$6.3M	Hold	76,450	–	–	0.01%	891
2017 Q2	$7.16M	Buy	76,450 +12,000	+19%	+$734K	0.01%	804
2017 Q1	$4.1M	Buy	64,450 +7,500	+13%	+$456K	0.01%	1097
2016 Q4	$2.53M	Buy	56,950 +3,900	+7%	+$137K	﹤0.01%	1404
2016 Q3	$1.91M	Sell	53,050 -2,000	-4%	-$42.9K	﹤0.01%	1543
2016 Q2	$755K	Buy	55,050 +6,200	+13%	+$90.6K	﹤0.01%	2124
2016 Q1	$905K	Buy	48,850 +9,950	+26%	+$211K	﹤0.01%	1958
2015 Q4	$1.36M	Hold	38,900	–	–	﹤0.01%	1590
2015 Q3	$3.58M	Buy	38,900 +9,100	+31%	+$788K	0.01%	953
2015 Q2	$2.62M	Buy	29,800 +5,000	+20%	+$428K	0.01%	1145
2015 Q1	$1.84M	Buy	24,800 +300	+1%	+$21.2K	﹤0.01%	1346
2014 Q4	$1.37M	Buy	24,500 +600	+3%	+$31.5K	0.01%	1532
2014 Q3	$1.08M	Sell	23,900 -400	-2%	-$16.7K	﹤0.01%	1616
2014 Q2	$1.01M	Buy	24,300 +1,300	+6%	+$67K	﹤0.01%	1725
2014 Q1	$1.59M	Buy	23,000 +4,900	+27%	+$360K	0.01%	1374
2013 Q4	$1.09M	Buy	18,100 +4,900	+37%	+$267K	﹤0.01%	1446
2013 Q3	$802K	Buy	13,200 +3,500	+36%	+$248K	﹤0.01%	1606
2013 Q2	$650K	Buy	+9,700	New	+$436K	﹤0.01%	1723

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Swiss National Bank's CLVS Position: Q2 2022 in Review

Swiss National Bank sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 291,900 shares — an estimated $590K sold.

Swiss National Bank first reported a position in CLVS in Q2 2013 and held it in 34 quarters. The position peaked at $7.16M in Q2 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

Swiss National Bank reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
Swiss National Bank sold 291,900 Clovis Oncology, Inc. shares in Q2 2022, an estimated $590K.
Swiss National Bank first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 34 quarters.
Swiss National Bank's Clovis Oncology, Inc. position peaked at $7.16M in Q2 2017.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Swiss National Bank's 13F filing for Q2 2022, filed 9 Aug 2022.